T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients
暂无分享,去创建一个
Kazumasa Yokoyama | Takashi Yamamura | Jun-ichi Satoh | J. Satoh | T. Kanda | Masayuki Ohta | Toshiro Saito | Toshiyuki Yamamoto | T. Yamamura | S. Miyake | S. Kikuchi | K. Yokoyama | Toshiyuki Yamamoto | Hiroyuki Onoue | H. Onoue | Toshiyuki Fukazawa | Mitsuru Kawai | Sachiko Miyake | Seiji Kikuchi | Toshiro Saito | Takashi Kanda | Megumi Nakanishi | Fumiko Koike | Toshimasa Aranami | Kyouichi Nomura | Kohei Ota | Masayuki Ohta | M. Kawai | K. Ota | T. Fukazawa | K. Nomura | T. Aranami | M. Nakanishi | F. Koike
[1] Gveric,et al. Insulin‐like growth factors and binding proteins in multiple sclerosis plaques , 1999, Neuropathology and applied neurobiology.
[2] H. Weiner,et al. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[4] R. Reynolds,et al. Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.
[5] J. Menonna,et al. Platelet‐derived growth factor‐α receptor‐positive oligodendroglia are frequent in multiple sclerosis lesions , 2001 .
[6] D. Hafler,et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.
[7] G. Opdenakker,et al. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis , 2003, The Lancet Neurology.
[8] S. Hulshof,et al. Cellular localization and expression patterns of interleukin‐10, interleukin‐4, and their receptors in multiple sclerosis lesions , 2002, Glia.
[9] N. Peress,et al. Glial transforming growth factor (TGF)-β isotypes in multiple sclerosis: differential glial expression of TGF-β1, 2 and 3 isotypes in multiple sclerosis , 1996, Journal of Neuroimmunology.
[10] P. Aarnisalo,et al. Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts. , 2004, Molecular endocrinology.
[11] R. Hirsch,et al. Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.
[12] Pierre Baldi,et al. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..
[13] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[14] L. Staudt,et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.
[15] L. Steinman,et al. Transcriptional analysis of targets in multiple sclerosis , 2003, Nature Reviews Immunology.
[16] A. Achiron,et al. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus , 2004, Clinical and experimental immunology.
[17] M. Ramanathan,et al. Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[18] S. Vukusic,et al. Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.
[19] Hong Zhang,et al. The FASEB Journal express article 10.1096/fj.02-1131fje. Published online September 4, 2003. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels , 2022 .
[20] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[21] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[22] R. Takayanagi,et al. cDNA cloning of a NGFI-B/nur77-related transcription factor from an apoptotic human T cell line. , 1995, Journal of immunology.
[23] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[24] J. Satoh,et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis , 2005, Neurobiology of Disease.
[25] Pingar Yang,et al. Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self- reactive T cells , 1996, The Journal of experimental medicine.
[26] C. Bisbal,et al. Cloning and Characterization of a RNase L Inhibitor. , 1995, The Journal of Biological Chemistry.
[27] J. Parisi,et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.
[28] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[29] L. Griffiths,et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. , 2003, Brain research. Molecular brain research.
[30] L. Staudt,et al. Gene expression physiology and pathophysiology of the immune system. , 2001, Trends in immunology.
[31] Lawrence Steinman,et al. Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.
[32] Nir Friedman,et al. Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity , 2004, Annals of neurology.
[33] Jorge R. Oksenberg,et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.
[34] Y. Itoyama,et al. Interferon beta-1b is effective in Japanese RRMS patients , 2005, Neurology.
[35] R. Rudick,et al. Defining interferon β response status in multiple sclerosis patients , 2004 .
[36] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[37] J. Satoh,et al. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis , 2003, Journal of Neuroimmunology.